Cat. No.: DAB-0012800
Product Information | |
---|---|
Clonality | Polyclonal |
Host Species | Rabbit |
Reactivity | Human, Mouse, Rat, Monkey |
Applications | WB, IP |
Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human RMP protein. Antibodies are purified by protein A and peptide affinity chromatography. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | URI1 |
UniProt No. | O94763 |
Gene ID | 8725 |
Gene Description | RMP, also known as URI, was described as an unconventional member of the prefoldin family of chaperones that are involved in actin and tubulin folding. Like conventional members of the α-class of PFDs, RMP contains N- and C-terminal α-helical coiled-coil structures connected by two β hairpins. In addition, RMP possesses an RPB5-binding segment and a long C-terminal acidic segment. It is posited that RMP exists as a component of a macromolecular complex within human cells and functions as a molecular scaffold to assemble a PFD complex containing other PFDs and proteins with functions in transcription and ubiquitination. Indeed, evidence is provided that RMP negatively modulates RNA polymerase II-dependent transcription by binding to TFIIF and RBP5 and is involved in mTOR signaling by coordinating the regulation of nutrient availability with gene expression. In accord with its ability to coordinate gene expression with nutrient availability, RMP was shown to be a mitochondrial substrate of S6K1. S6K1-mediated phosphorylation of RMP at Ser371 triggers a series of biochemical events that constitute a negative feedback loop, in part, aimed at restraining S6K1 survival signaling and ensuring that the mitochondrial threshold for apoptosis corresponds to availability of nutrients and growth factors. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.